Insider Selling: Supernus Pharmaceuticals (NASDAQ:SUPN) CEO Sells 10,235 Shares of Stock

Key Points

• Supernus Pharmaceuticals CEO Jack Khattar sold 10,235 shares of the company's stock for approximately $491,484.70, resulting in a 0.89% decrease in his ownership.
• The stock price of Supernus Pharmaceuticals increased by 0.4% on Tuesday, reaching $47.79, with a market capitalization of $2.68 billion.
• Recent analyst ratings have been positive, with price targets raised, including a new target of $63.00 from Cantor Fitzgerald and an average price target of $51.50 across analysts.

Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN - Get Free Report) CEO Jack Khattar sold 10,235 shares of the business's stock in a transaction dated Monday, September 29th. The shares were sold at an average price of $48.02, for a total transaction of $491,484.70. Following the completion of the sale, the chief executive officer owned 1,144,336 shares of the company's stock, valued at approximately $54,951,014.72. This represents a 0.89% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at this link.

Supernus Pharmaceuticals Stock Up 0.4%

Shares of NASDAQ SUPN traded up $0.19 during trading hours on Tuesday, hitting $47.79. 497,508 shares of the stock were exchanged, compared to its average volume of 644,992. The company has a market cap of $2.68 billion, a PE ratio of 41.56 and a beta of 0.79. The firm has a fifty day moving average price of $42.32 and a 200-day moving average price of $35.72. Supernus Pharmaceuticals, Inc. has a 12 month low of $29.16 and a 12 month high of $48.44.

Analyst Upgrades and Downgrades

Several research firms recently commented on SUPN. Piper Sandler boosted their price objective on shares of Supernus Pharmaceuticals from $36.00 to $40.00 and gave the stock a "neutral" rating in a research note on Friday, August 29th. Cantor Fitzgerald boosted their price objective on shares of Supernus Pharmaceuticals from $46.00 to $63.00 and gave the stock an "overweight" rating in a research note on Tuesday. Wall Street Zen upgraded shares of Supernus Pharmaceuticals from a "hold" rating to a "buy" rating in a research note on Saturday, August 2nd. Finally, Zacks Research upgraded shares of Supernus Pharmaceuticals from a "hold" rating to a "strong-buy" rating in a research note on Wednesday, September 17th. One investment analyst has rated the stock with a Strong Buy rating, two have issued a Buy rating and one has given a Hold rating to the stock. According to MarketBeat, the stock has an average rating of "Buy" and an average price target of $51.50.

Institutional Inflows and Outflows

A number of hedge funds have recently bought and sold shares of the stock. Corient Private Wealth LLC acquired a new position in Supernus Pharmaceuticals during the 2nd quarter valued at approximately $248,000. Osaic Holdings Inc. increased its stake in shares of Supernus Pharmaceuticals by 211.5% in the second quarter. Osaic Holdings Inc. now owns 1,956 shares of the specialty pharmaceutical company's stock worth $63,000 after acquiring an additional 1,328 shares during the period. China Universal Asset Management Co. Ltd. increased its stake in shares of Supernus Pharmaceuticals by 9.8% in the second quarter. China Universal Asset Management Co. Ltd. now owns 21,245 shares of the specialty pharmaceutical company's stock worth $670,000 after acquiring an additional 1,893 shares during the period. Squarepoint Ops LLC increased its stake in shares of Supernus Pharmaceuticals by 63.8% in the second quarter. Squarepoint Ops LLC now owns 119,978 shares of the specialty pharmaceutical company's stock worth $3,782,000 after acquiring an additional 46,711 shares during the period. Finally, Thrivent Financial for Lutherans increased its stake in shares of Supernus Pharmaceuticals by 1.5% in the second quarter. Thrivent Financial for Lutherans now owns 41,170 shares of the specialty pharmaceutical company's stock worth $1,298,000 after acquiring an additional 611 shares during the period.

About Supernus Pharmaceuticals

Supernus Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. The company's commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prophylaxis of migraine headache; and Oxtellar XR, an extended release oxcarbazepine for the monotherapy treatment of partial onset seizures in adults and children between 6 to 17 years of age.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.